BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 11309274)

  • 1. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
    Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ
    Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma.
    Seftor RE; Seftor EA; Koshikawa N; Meltzer PS; Gardner LM; Bilban M; Stetler-Stevenson WG; Quaranta V; Hendrix MJ
    Cancer Res; 2001 Sep; 61(17):6322-7. PubMed ID: 11522618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase promotes the aggressive melanoma phenotype.
    Hess AR; Postovit LM; Margaryan NV; Seftor EA; Schneider GB; Seftor RE; Nickoloff BJ; Hendrix MJ
    Cancer Res; 2005 Nov; 65(21):9851-60. PubMed ID: 16267008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasculogenic mimicry--potential target for tumor therapy].
    Yue WY; Chen ZP
    Ai Zheng; 2006 Jul; 25(7):914-6. PubMed ID: 16831290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors.
    Hess AR; Margaryan NV; Seftor EA; Hendrix MJ
    Dev Dyn; 2007 Dec; 236(12):3283-96. PubMed ID: 17557303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular plasticity of human melanoma cells.
    Hendrix MJ; Seftor EA; Hess AR; Seftor RE
    Oncogene; 2003 May; 22(20):3070-5. PubMed ID: 12789282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
    Hess AR; Seftor EA; Seftor RE; Hendrix MJ
    Cancer Res; 2003 Aug; 63(16):4757-62. PubMed ID: 12941789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.
    Ruf W; Seftor EA; Petrovan RJ; Weiss RM; Gruman LM; Margaryan NV; Seftor RE; Miyagi Y; Hendrix MJ
    Cancer Res; 2003 Sep; 63(17):5381-9. PubMed ID: 14500372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of vasculogenic mimicry in colorectal cancer.
    Baeten CI; Hillen F; Pauwels P; de Bruine AP; Baeten CG
    Dis Colon Rectum; 2009 Dec; 52(12):2028-35. PubMed ID: 19934926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The involvement of apoptosis in melanoma vasculogenic mimicry.
    Vartanian AA; Burova OS; Stepanova EV; Baryshnikov AY
    Melanoma Res; 2007 Feb; 17(1):1-8. PubMed ID: 17235236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasculogenic mimicry: current status and future prospects.
    Zhang S; Zhang D; Sun B
    Cancer Lett; 2007 Sep; 254(2):157-64. PubMed ID: 17306454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
    Carles-Kinch K; Kilpatrick KE; Stewart JC; Kinch MS
    Cancer Res; 2002 May; 62(10):2840-7. PubMed ID: 12019162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma.
    Hendrix MJ; Seftor EA; Hess AR; Seftor RE
    Nat Rev Cancer; 2003 Jun; 3(6):411-21. PubMed ID: 12778131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasculogenic mimicry.
    Folberg R; Maniotis AJ
    APMIS; 2004; 112(7-8):508-25. PubMed ID: 15563313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry.
    Hess AR; Seftor EA; Gruman LM; Kinch MS; Seftor RE; Hendrix MJ
    Cancer Biol Ther; 2006 Feb; 5(2):228-33. PubMed ID: 16481735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro.
    Lissitzky JC; Parriaux D; Ristorcelli E; Vérine A; Lombardo D; Verrando P
    Cancer Res; 2009 Feb; 69(3):802-9. PubMed ID: 19176384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spatial distribution of monosomy 3 and network vasculogenic mimicry patterns in uveal melanoma.
    Meir T; Zeschnigk M; Masshöfer L; Pe'er J; Chowers I
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):1918-22. PubMed ID: 17460242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.
    Sood AK; Fletcher MS; Coffin JE; Yang M; Seftor EA; Gruman LM; Gershenson DM; Hendrix MJ
    Am J Obstet Gynecol; 2004 Apr; 190(4):899-909. PubMed ID: 15118611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix-loop-helix Id2 (inhibitor of DNA binding 2).
    Su F; Li B; Wang J; Xu X; Ren R; Li L; Gao F; Liu X
    Graefes Arch Clin Exp Ophthalmol; 2009 Mar; 247(3):411-9. PubMed ID: 19043732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.